Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2147/COPD.S102962 http://scihub22266oqcxt.onion/10.2147/COPD.S102962 C4869636!4869636 !27274218     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27274218 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Int+J+Chron+Obstruct+Pulmon+Dis 2016 ; 11 (ä): 971-9 Nephropedia Template TP {{tp|p=27274218 |t=2016. A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62 5/25 ?g on health-related quality of life in patients with COPD |pdf=|usr=}}{{27274218 }} gab.com Text A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62 5/25 g on health-related quality of life in patients with COPD JO: Int J Chron Obstruct Pulmon Dis http://www.kidney.de/pget.php?&tw=1&pmid=27274218 #FOAvip BACKGROUND: The combination of the inhaled muscarinic antagonist umeclidinium (UMEC) with the long-acting ?2-agonist vilanterol (VI) has been shown to provide significant improvements in lung function compared with UMEC, VI, or placebo (PBO) in patients with chronic obstructive pulmonary disease (COPD). This study was specifically designed to support these findings by assessing health-related quality of life and symptomatic outcomes in a similar population. METHODS: This was a 12-week multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Eligible patients were randomized 1:1 to receive once-daily UMEC/VI 62.5/25 ?g (via ELLIPTA(®) dry powder inhaler) or PBO for 12 weeks. The primary endpoint was St George's Respiratory Questionnaire (SGRQ) total score at day 84. Secondary efficacy endpoints included rescue albuterol use (puffs/day) over weeks 1-12 and trough forced expiratory volume in 1 second on day 84. Adverse events were also assessed. RESULTS: A total of 496 patients were included in the intent-to-treat population in the UMEC/VI (n=248) and PBO (n=248) treatment groups. UMEC/VI 62.5/25 ?g provided a significant and clinically meaningful improvement in SGRQ total score at day 84 versus PBO (difference between treatments in SGRQ total score change from baseline: -4.03 [95% confidence interval {CI}: -6.28, -1.79]; P<0.001). UMEC/VI 62.5/25 ?g resulted in a statistically significant reduction in rescue albuterol use versus PBO (-0.7 puffs/day [95% CI: -1.1, -0.4]; P<0.001). UMEC/VI 62.5/25 ?g provided a significant and clinically meaningful improvement in trough forced expiratory volume in 1 second on day 84 versus PBO (122 mL [95% CI: 71, 172]; P<0.001). The incidence of adverse events was similar between treatments (32% and 30% of patients in the UMEC/VI 62.5/25 ?g and PBO groups, respectively). CONCLUSION: The results of this study demonstrate that treatment with UMEC/VI 62.5/25 ?g provides clinically important improvements in SGRQ and rescue medication use versus PBO in patients with moderate-to-very-severe COPD. Twit Text FOAVip A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62 5/25 g on health-related quality of life in patients with COPD ????Int J Chron Obstruct Pulmon Dis http://www.kidney.de/pget.php?&tw=1&pmid=27274218 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27274218 #FOAvip English Wikipedia <ref>{{Cite pmid|27274218 }}</ref> A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62 5/25 ?g on health-related quality of life in patients with COPD #MMPMID27274218 Siler TM ; Donald AC ; O'Dell D ; Church A ; Fahy WA Int J Chron Obstruct Pulmon Dis 2016[]; 11 (ä): 971-9 PMID27274218 show ga BACKGROUND: The combination of the inhaled muscarinic antagonist umeclidinium (UMEC) with the long-acting ?2-agonist vilanterol (VI) has been shown to provide significant improvements in lung function compared with UMEC, VI, or placebo (PBO) in patients with chronic obstructive pulmonary disease (COPD). This study was specifically designed to support these findings by assessing health-related quality of life and symptomatic outcomes in a similar population. METHODS: This was a 12-week multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Eligible patients were randomized 1:1 to receive once-daily UMEC/VI 62.5/25 ?g (via ELLIPTA(®) dry powder inhaler) or PBO for 12 weeks. The primary endpoint was St George's Respiratory Questionnaire (SGRQ) total score at day 84. Secondary efficacy endpoints included rescue albuterol use (puffs/day) over weeks 1-12 and trough forced expiratory volume in 1 second on day 84. Adverse events were also assessed. RESULTS: A total of 496 patients were included in the intent-to-treat population in the UMEC/VI (n=248) and PBO (n=248) treatment groups. UMEC/VI 62.5/25 ?g provided a significant and clinically meaningful improvement in SGRQ total score at day 84 versus PBO (difference between treatments in SGRQ total score change from baseline: -4.03 [95% confidence interval {CI}: -6.28, -1.79]; P<0.001). UMEC/VI 62.5/25 ?g resulted in a statistically significant reduction in rescue albuterol use versus PBO (-0.7 puffs/day [95% CI: -1.1, -0.4]; P<0.001). UMEC/VI 62.5/25 ?g provided a significant and clinically meaningful improvement in trough forced expiratory volume in 1 second on day 84 versus PBO (122 mL [95% CI: 71, 172]; P<0.001). The incidence of adverse events was similar between treatments (32% and 30% of patients in the UMEC/VI 62.5/25 ?g and PBO groups, respectively). CONCLUSION: The results of this study demonstrate that treatment with UMEC/VI 62.5/25 ?g provides clinically important improvements in SGRQ and rescue medication use versus PBO in patients with moderate-to-very-severe COPD. |*Quality of Life [MESH] |Administration, Inhalation [MESH] |Adrenergic beta-2 Receptor Agonists/*administration & dosage/adverse effects [MESH] |Aged [MESH] |Albuterol/administration & dosage [MESH] |Benzyl Alcohols/*administration & dosage/adverse effects [MESH] |Bronchodilator Agents/*administration & dosage/adverse effects [MESH] |Chlorobenzenes/*administration & dosage/adverse effects [MESH] |Double-Blind Method [MESH] |Drug Combinations [MESH] |Europe [MESH] |Female [MESH] |Forced Expiratory Volume [MESH] |Humans [MESH] |Intention to Treat Analysis [MESH] |Lung/*drug effects/physiopathology [MESH] |Male [MESH] |Middle Aged [MESH] |Muscarinic Antagonists/*administration & dosage/adverse effects [MESH] |Pulmonary Disease, Chronic Obstructive/diagnosis/*drug therapy/physiopathology/psychology [MESH] |Quinuclidines/*administration & dosage/adverse effects [MESH] |Recovery of Function [MESH] |Severity of Illness Index [MESH] |Surveys and Questionnaires [MESH] |Time Factors [MESH] |Treatment Outcome [MESH]A randomized, parallel-group study to evaluate the efficacy of umecl(epmc).pdf DeepDyve Pubget Overpricing